Skip to content

Prospective Cohort Study on Antibiotic Course and Efficacy After Two-stage Revision in PJI.

Effect of Antibiotic Treatment Course on Clinical Outcome After Two-stage Revision of Prosthetic Joint Infection: A Prospective Cohort Study.

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT05284318
Acronym
PACER-PJI
Enrollment
500
Registered
2022-03-17
Start date
2021-12-01
Completion date
2026-12-31
Last updated
2022-03-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Anti-Bacterial Agents, Periprosthetic Joint Infection

Keywords

Periprosthetic joint infection, Second-stage revision, Anti-Bacterial Agents

Brief summary

This is a multicenter prospective cohort study in which patients were evaluated by inclusion and exclusion criteria before phase II revision surgery. Eligible patients will be included in this study after signing the informed consent form. After the second stage revision, according to the patient's symptoms and examination results, the attending physician used a reasonable antibiotic treatment scheme (including intravenous and oral medication). All patients voluntarily participated in the study and signed informed consent. During the treatment period, all prospective patients underwent clinical evaluation at the time points of 1, 3, 6, 12, 18 and 24 months after the start of antibiotic treatment after phase II revision. The infection control rate of patients was evaluated by follow-up at least 2 years after operation, so as to analyze the effect of antibiotic treatment course after two-stage revision of periprosthetic joint infection.

Detailed description

Inclusion criteria: 1. A diagnosis of PJI was made according to MSIS criteria 2. Received spacer implantation and a full course of antibiotic treatment (at least 6 weeks), the patient was clinically determined to have infection control and underwent secondary joint revision. 3. Age ≥18 years old 4. The patient voluntarily participated in the study, and was physically and mentally tolerant to the treatment process and various tests of the study. He has signed an informed consent form and passed the examination of all the hospital ethics committees participating in the study. Exclusion criteria: 1. Follow up data were not available; 2. The investigator judged that the patient no longer met the criteria of the study due to compliance problems. Recruiting time:2021.10 -2023.10.31 Interventions Group:No Sample size:500 Study Population Description: Patients who underwent secondary replantation surgery for prosthetic joint infection at the First Affiliated Hospital of Fujian Medical University and other sub-centers were selected.

Interventions

DRUGAntibiotics treatment

After receiving intravenous antibiotics treatment for 2 weeks, and clinician determines whether to continue with any antibiotics.

Sponsors

First Affiliated Hospital of Fujian Medical University
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

\- 1. A diagnosis of PJI was made according to MSIS criteria. 2. Received spacer implantation and a full course of antibiotic treatment (at least 6 weeks), the patient was clinically determined to have infection control and underwent secondary joint revision. 3\. Age ≥18 years old. 4. The patient voluntarily participated in the study, and was physically and mentally tolerant to the treatment process and various tests of the study. He has signed an informed consent form and passed the examination of all the hospital ethics committees participating in the study.

Exclusion criteria

* 1\. Follow-up data not available. 2. Researchers judge that patients no longer meet the standards of the study due to compliance problems

Design outcomes

Primary

MeasureTime frameDescription
Clearance rate of infection31, December,2026Number of subjects with infection cleared/total number of subjects who completed follow-up

Countries

China

Contacts

Primary ContactFang
9738006@qq.com18084768503

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026